AUTHOR INDEX

Abadla, A. R., 197 Bowers, Gary D., 724 Chung, Woon-Gye, 1263 Eddershaw, Peter J., 724 Abbott, Frank S., 1383 Boyd, Michael R., 651 Clank, B., 922 Edwards, Robert J., 929 Abdallah, Claude, 584 Bozler, Gerhard, 1206 Clarke, Stephen E., 251 Ehlhardt, William J., 910 Acheampong, Andrew A., 708 Bracken, William, 736 Coassolo, P., 1051 Ehninger, Gerhard, 94 Adams, Delyth A., 929 Bradbury, Alan, 393 Coldham, N. G., 501 Ekins, Sean, 1274 Adams, Paula C., 982 Brady, Alexandra N., 60 Collins, Michael A., 102 Elder, Cheryl A., 776 Ader, Jean-Claude, 813 Brashear, Wayne T., 1202 Colthup, P. V., 1225 Elfarra, Adnan A., 846 Agen, Cristiana, 713 Brendel, K., 497 Conroy, Robert, 904 Ellis, Andrew G., 363 Aigbirhio, Franklin I., 832 Brendel, Klaus, 327 Cooper, A. E., 922 Ellis, Joan D., 688 Albet, Carlos, 976 Brennan, Beverley, 349 Coutts, Ronald T., 525 Ellis, Martin K., 102 Ali, Syed F., 881 Brewer, T. 0., 1, 18 Creveling, Cyrus R., 430 El Mansouri, S., 227 Anari, M. Reza, 536 Brien, James F., 1248 Cribb, Alastair, 671 Endo, Takahiko, 1022 Anders, M. W., 48, 124, 875 Bugelski, Peter J., 1044 Cribb, Alastair E., 406, 536 Escousse, Andr#{233},343 Anderson, Christopher D., 1286 Buhler, Donald R., 1263 Crom, William R., 1110 Estabrook, R. W., 765 Anderson, Kathleen, 799 Bull, Richard J., 1412 Crooks, Peter A., 1175 Evans, Frederick E., 1417 Andersson, Paul, 137 Bullock, Peter, 736 Crowl, Robert, 904 Evans, William E., 1 1 10 Andrews, Paul A., 178 232 Burka, Leo T., Crowley, Jan R., 786 Anglada, Lluis, 976 Burke, M. Danny, 1274 Facchine, Kevin L., 869 Cutler, N. Shame, 595 Angus, P. W., 485 Burlingame, Alma L., 369 Fagliano, Jerald A., 607 Faiman, Morris D., 1153 Appleton, Martin L., 595 Burmaster, Steve D., 631 Dahl, A. R., 529 Falany, Charles N., 945 Arison, Byron H., 266 Buronfosse, Thierry, 160 Danesi, Romano, 713 Astrom, Anders, 137 Busch, Ulrich, 1206 Fasanmade, Adedigbo A., 573 Dannecker, Robert, 321, 327 Fasco, Michael J., 1339 Atta-Asafo-Adjei, E., 1431 Buters, Jeroen T. M., 696 Dave, M., 501 Augustijns, Patrick F., 1372 Fedorov, Ivan I., 655 Davies, Donald S., 929 Fenselau, Catherine, 119 Cannell, Richard J. P., 724 Davies, Malonne I., 1072 Ferrero, J. L., 765 Baba, Takahiko, 1195 Carbonaro, Michael A., 1044 Davis, Charles B., 1028, 1044 Ferrero, James L., 1143, 1163 Bader, Augustinus, 1315 Carlson, Timothy J., 749 Dawson, Michael J., 724 Finkelstein, Martin B., 124 Bai, Xigeng, 993 Carrel, Barb K., 757 Dean, Dennis C., 1126 Finley, Brent, 607 Bailey, G. S., 965 Cashman, John R., 1143 de Bruijn, E. A., 433 Fischer, VoWer, 327 Baker, Max T., 60 Castagnoli, Neal, Jr., 749 De Francesco, L., 197 Fisher, M. B., 1431 Balani, Suresh K., 185, 266, 688 Castell, Jos#{233}V., 553 De Graeve, Jean, 1305 Fisher, Robert A., 415 Baron, Jeffrey, 1346 Castillo, Marta, 566 de Groot, M. J., 667 Fisher, Robyn L., 327 Barton, H. A., 1202 Castle, Pamela J., 1037 DeHart, Peter D., 441 Fong, Kei-Lai, 799 Bazin-Redureau, M., 1400 Catlow, John, 916 Dekant, Wolfgang, 861 Fortin, R., 1325 Beauchamp, Lilia, 1242 Cerniglia, Carl E., 1417 Delatour, Paul, 160 Foster, David J. R., 892 Bellward, Gail D., 1407 Chakravarty, Prasun K., 207 de Leon, Jesus H., 1354 Foumel-Gigleux, Sylvie, 1305 Bend, John R., 577 Chang, I. Y., 529 del Tacca, Mario, 713 Franklin, Michael R., 1379 Benet, Leslie Z., 369, 825, 900, Chang, Tsun, 441 de Miranda, Paulo, 1242 Fredenbung, Andrea M., 1178 1099 Chapelle, P., 1400 Demuth, Sandra 0., 1028 Freeman, James P., 1417 Benfenati, E., 113 Chauret, N., 65, 1325 De Sousa, G., 1051 Freemantle, Christopher A. J., 832 Benoit, Etienne, 160 Chay, Sylvia H., 916 Freund, Stefan, 94 Bergeron, Raymond J., I 1 17 Chen, Guangping, 1346, 1390 De Sousa, Georges, 308 Friesen, R., 1325 Besner, Jean Guy, 584 Chen, 1-Wu, 266, 730 Dickinson, Ronald G., 119 Fujii, Y., 28 Bhagwat, Shripad V., 651 Chen, Roger, 207 Dimova, Hnistina, 1117 Ding, Andreas, 369 Fujikawa, A., 28 Bhalla, Kapil N., 506 Chenery, Richard, 349 Fujio, Nami, 999 Bhargava, Ravi, 1110 Chenery, Richard J., 251 di Paolo, Antonello, 713 Fujioka, M., 28 Bijloo, G. J., 667 Cheng, Lawrence K., 631, 806 Distefano, Emma W., 201, 610 Fujisawa, Masae, 1022 Binienda, Zbigniew, 881 Cheraghali, A. Majid, 223 Divakaruni, Prasanna, 295 Fujita, Shoichi, 1268, 1301 Binkley, Shelly N., 1231 Chesson, S. M., 951 Dixon, C. M., 1225 Fujitsu, T., 28 Birner, Gerhard, 861 Chiba, Masato, 622 Dolan, M. Eileen, 1394 Fukuyama, Takako, 779 Bischer, Alfred, 900, 1099 Chikai, Toshiyuki, 35 Domergue, Jacques, 1253 Funae, Yoshihiko, 610, 999 Bishop, Warren P., 299 Ching, Michael S., 190 Donato, M. Teresa, 553 Furst, Sylvia M., 590 Blake, P., 433 Chiu, Shuet-Hing Lee, 207, 1126 Draile, Henning, 1315 Blake, Timothy, 799 Cho, Arthur K., 201, 610 Draper, Alison, 736 Galceran, M. Teresa, 976 Blanz, Joachim, 94 Cho, Joon H., 840 Dreyer, Geoffrey, 799 Gandolfi, A. J., 497 Boado, Ruben J., 55, 1297 Cho, Joo Youn, 460 Dubd, D., 1325 Ganguly, Tanmoy C., 945 Bocci, Guido, 713 Cho, Yong-Baik, 1280 Ducharme, Y., 65 Gargas, Michael, 607 Bockbrader, Howard N., 441 Choudhuri, Supratim, 1291 Duescher, Renee J., 846 Garland, William A., 904 Boehlert, C. C., 1225 Choudhury, Ruksana, 314 Duffel, Michael W., 1346 Garton, Kyle J., 1426 Bonfils, Claude, 1253 Chouini-Lalanne, Nadia, 813 Duha.rt, Benjamin, Jr., 1417 Garver, Eric, 799 Borchardt, Ronald T., 1372 Chow, Moses S. S., 449 Dulik, Deanne M., 1004 Geerts, Rita J. F., 216 Born, Stephanie L., 702 Christians, Uwe, 1315 Du Souich, Patrick, 279, 584 Gerstenberg, B., 143 Bornheim, Lester M., 825 Chu, Chung K., 655 Dwoskin, Linda P., 1175 Ghabrial, H., 485 Boudinot, F. Douglas, 655, 1368 Chu, Teresa Y. Y., 201 Dwyer, Lynn M., 688 Ghabrial, Hany, 190 1436 AUTHOR INDEX 1437

Gilard, Veronique, 813 Holland, Mary L., 90 Kim, Dae-Kee, 1280 Lin, Jiunn H., 266, 730, 1008 Gullet, Gerard, 1253 Hollenberg, Paul F., 786 Kim, Hyesook, 818 Lin, Lena Y., 201, 610 Girard, Y., 1325 Honchel, Ronald, 398 Kim,HyoJ., 840 Ling, Kah-Hiing J., 631 Gires, P., 1400 Hook, Robert H., 631 Kim, Kelly Y., 825 Lipe, George, 881 Gochield, Michael, 607 Hone, Toshiharu, 999 Kim, Key H., 1280 Lipscomb, J. C., 1202 G#{243}mez-Lechdn, M. Jos#{233},553 Horton, M. N., 377 Kim, S. G., 529 Liu, Thao Chao, 246 Gonschior, Ann-Katrin, 1315 Hoshi, Hidenobu, 1301 Kim, Sang Geon, 460 Logan, C. J., 922 Gonzalez, Frank J., 696 Hosokawa, Masakiyo, 1022 Kimelman, David, 72, 83 Loi, Cho-Ming, 1335 Gordon, John D., 1383 Houston, J. Brian, 349, 393 King, Andrew R., 119 Loizou, George D., 875 Goudonnet, Herv#{233},343 Houtman, Jon, 398 Klaassen, Curtis D., 840 Longin-Sauvageon, Christiane, Graham,P.J., 501 Huang, Zeqi, 1339 Kleiner, Heather E., 1136 160 Green, Mitchell D., 299 Hughes, J. Michael B., 832 Klekotka, Paul A., 1434 L#{248}nning,P. E., 377 Green, Trevor, 102 Huskey, Su-Er W., 1126 Knaggs, Andrew R., 724 Lorenzon, Giocondo, 308 Griffin, D. A., 965 Knaus, Edward E., 223 Lu, D. Robert, 1368 Griffin, Gear#{243}idP., 406 Ichimura, Fujio, 1220 Kocarek, Thomas A., 415, 681 Lu,Y.H., 154 Griffm, Robert J., 232 Idowu, 0. R., 1, 18 Kolars, Joseph C., 1315 Luchetta, Gabriel, 1117 Grimm, Scott W., 577 Iga, Tatsuji, 718 Korzekwa, Kenneth R., 696 Lunte, Craig E., 1072 Guaitani,A., 197 Imaoka, Susumu, 999 Kracko, D. A., 529 Guengerich, F. Peter, 285, 438, Inazawa, Kazuhiru, 35 Kraft, Joan Creech, 72, 83, 1058 Machinist, Joseph M., 1163 1315, 1339 Innocenti, Federico, 713 Krasny, Harvey C., 1242 Macleod, Michael C., 854 Guertler, Joseph, 327 Inoue, Katsuhiro, 430 Krasnykh, Victor, 945 Madan, Ajay, 1153 Guo, Zuyo, 438 Iwaki, Masahiro, 900, 1099 Krenitsky, Thomas A., 1242 Madden, Stephen, 929 Gupta, Elora, 1394 Iwasaki, K., 28 Kukulka, M. J., 765 Madhu, Cherukury, 840 Gupta, N., 1085 Iwata, Nobuhisa, 1022 Kukulka, Michael J., 1143 Maes, R. A. A., 433 Guzelian, Philip S., 415 Iyer, Krishna R., 749 Kumagai, Yoshito, 610 Magdalou, Jacques, 343, 1305 Kumar, Gondi N., 506, 1286 Magistrelli, A., 1 13 Hackbarth, Ingelore, 1315 Jaeck, D., 1051 Kumar, Rakesh, 223 Mahle, D. A., 1202 Hall, Caroline, 1383 Jamali, Fakhreddin, 240 Kummer, Michael, 1206 Malet-Martino, Marie-C., 813 Hall, M., 922 Jarvi, Eric J., 1335 Kunze, Kent L., 490, 659 Manchee, Gary R., 724 Hall, Tse Wai, 1188 Jennerwein, Margreth, 178 Kuo, Be-Sheng, 757 Mangold, James B., 615 Halm, Kathy A., 869 Jeong, Hye Gwang, 285 Kuo, Chung-Liang, 935 Manouilov, Konstantine K., 655 Halpert, James R., 577, 702, 1434 Jesthi, Pradipta K., 595 Kuo, George Y., 1004 Mansi, J., 433 Hamaguchi, Tomoyuki, 35 Jimmo, Sandra L., 1248 Kwan, Eddie, 1383 Marchant, Nicola C., 1274 Hamdoune, Mohamed, 343 John, Gilbert H., 702 Kwok, Deborah C., 1028 Marks, Gerald S., 1248 Hansen, K. T., 667 Johnson, John T., 60 Martell, Karen J., 1354 Hanson, Beverly J., 441 Johnson, Ted, 916 Labroo, Rita B., 490 Martinet, M., 1400 Hara, Shuichi, 1022 Jones, A. Daniel, 129, 422 La Du, Bert N., 935 Martino, Robert, 813 Hardwick, James P., 696 Jones, Jeffrey P., 749 Lake, B. G., 501 Masgrau, Elisabeth, 887 Harlow, Greg R., 702 Jones, Terry, 832 Lam, Gilbert N., 603 Masmoudi, Taoufik, 343 Harper, P. G., 433 Jdnsson, Gunilla, 137 Lambert, C., 922 Maspeis, L., 676 Harrell, Andrew W., 251 Jordan, M. C., 922 Lam#{233},Michael W., 129, 422 Masubuchi, Yasuhiro, 999 Hart, Timothy K., 1028 Joseph, Gerald, 799 Lamiable, D., 988 Masuda, Makihiko, 1268, 1301 Harvison, Peter J., 107 Juchau, Mont R., 72, 83, 1058 Lampen, Alfons, 1315 Mathai, Leena, 266 Hashmi, Mazzaz, 1362 Jung, Ki Hwa, 460 Lang, Nicholas P., 518 Mather, Laurence E., 334 Hata, T., 28 Jusko, William J., 573 Lash, Lawrence H., 846 Mathews, Brad S., 757 Hawksworth, Gabrielle M., 1274 Lau, Serrine S., 1136 Matsubara, Takashi, 1195 Hayes, Karen A., 349 Kadlubar, Fred F., 518 Laurenzana, Elizabeth M., 271 Matsuda, H., 28 Hayes, Michael, 832 Kadono, Kyoko, 35 Lavrijsen, Karel, 354 Matsunaga, Tamihide, 261 He, Minxia, 659 Kaltenbach, M., 988 Lawton, M. P., 1431 Matsushita, Ryo, 1220 Heinzel, Gunther, 1206 Kamata, Kazuo, 35 Leclerq, M., 227 Maurel, Patrick, 1253 Hendrickx, Jan, 354 Kaminski, Donald R., 303 Lee, Daniel, 398 Maurer, Gerard, 321 Hepburn, Timothy W., 1028, 1044 Kaminsky, Laurence S., 1339 Lee, Heeyong, 285 Maurice, H#{233}l#{232}ne,279 Herber, Regine, 1305 Kane, Robert E., 303 Lee, Hye Suk, 285 Mautz, Douglas S., 513 Hercelin, Bernard, 1305 Kang, Young-Sook, 55, 1297 Lee, R. D., 765 Mayer, Michael D., 1163 H#{233}roux,Lucie, 279 Kapil, Ram P., 603 Leeson, Gerald A., 631 McCague, R., 377 Herzyk, Danuta J., 1028 Kaschke, Siegfrid, 1206 Leland, Michelle, 1028 McClelland, R. A., 590 Heykants, Jos, 354 Katashima, Masataka, 718 Lemke, Leslie E., 559 McClelland, Robert A., 246 Heykants, Joseph J. P., 216 Kauffman, Laura R., 266, 688 Levine, Marc, 1407 McDonagh, Antony F., 369, 1099 Heys, Richard, 799 Kawahara, Seiichi, 35 Lewis, J. L., 529 McLaughlin, Brian E., 1248 Hickman, Dean, 473 Kazusaka, Akio, 1268, 1301 Li, Albert P., 303 McLean, Cohn F., 334 Higaki, Kazutaka, 35 Keller, Blandine, 321, 327 Li, C., 65, 1325 McMillan, Joellyn M., 1286 Highley, M. S., 433 Kelly, C., 1 Li, Jianmin, 825 McNally, William P., 441 Higuchi, Saburo, 1214 Kerr,B.M., 1225 Li, Mm, 1175 McNamara, Patrick J., 465 Hiratsuka, Akira, 201, 610 Kestell, Philip, 363 Liberato, Daniel J., 904 McQueen, Charlene A., 559 Ho, John, 757 Kharasch, Evan D., 490, 1426 Lin, Dong-Xin, 518 Mehta, Samir C., 1368 1438 AUTHOR INDEX

Mehvar, Reza, 637 Ohshima, Tohru, 1220 Ramjit, Harri G., 185 Serabjit-Singh, C. J., 1225 Meinwald, Jerrold, 1426 Okita. Janice Rice, 1037 Rasmusson, Gary H., I 126 Sewing, Karl-F., 1315 Merdink, James L., 1037 Okita, Richard T., 1037 Ravindranath, Vijayalakshmi, 651 Shackleton, Martha, 708 Meuldermans, Willem, 354 Olson, Michael J., 60 Reddick, Wilburn E., 1110 Sharer, Jane E., 1231 Meuldermans, Willem E. G., 216 Olsson, Per, 832 Reddy, Satya, 818 Shen, Danny D., 513 Meurer, Kathryn A., 1178 Ortiz Dc Montellano, Paul R., Reith, M. Kelly, 63 1 , 806 Shet, M. S., 765 Meyer, Em, 321 1181 Renner, Ulf, 94 Shet, Manjunath S., 1163 Miller, Randall R., I I 26 Ostovic, Drazen, 730 Renton, Kenneth W., 536 Shimamoto, Yoshinori, 1301 Miller, Randy R., 266 Ouellet, Dani#{233}leM.-C., 478 Rettie, A. E., 1431 Shimatani, K., 28 Milne, Robert W., 334 Overhauser, Joan, 398 Rewcastle, Gordon W., 363 Shipley, Lisa A., 1231 Mizsak, Steven A., 383 Owens, S. Michael, 271 Reynolds, James, 637 Shiraga, T., 28 Modest, E. J., 1 13 Rho, Jung Koo, 285 Shore, Leonard J., 119 Modi, Marlene W., 776 Page, Brian C., 832 Rhodes, Christopher G., 832 Shou, Magang, 696 Momerency, G., 433 Palamanda, hiram R., 473 Rhodes, Gerald R., 1028 Shu, Arthur, 799 Monbaliu, Johan, 354 Pang, K. S., 166 Richards, Lauren E., 600 Shulkes, Arthur, 190 Monks, Terrence J., I 136 Pang, K. Sandy, 255, 622 Richmond, H., 922 Sidebottom, Philip J., 724 Monshouwer, M., 44 Pardridge, William M., 55, 1297 Rickert, Douglas E., 982 Sim, Edith, 473 Monshouwer, Mario, 542 Park, B. Kevin, 929 Riggs, K. Wayne, 1383 Singh, Surinder, 314 Moore, A. S., 501 Park, G. R., 1225 Riley, R. J., 922 Sivapathasundaram, S., 501 Morgan, D. J., 485 Parker, Jean C., 846 Ring, John A., 190 Skinner, Thomas L., I 178 Morgan, Denis 3., 190 Parker, William B., 881 Roberts, Stephen M., 664 Sladek, Norman E., 1080 Parkinson, Andrew, 736, 1 153 Morgan, S. E., 497 Rodrigues, A. D., 642, 765 Slikker, William, Jr., 881 Patanella, James E., 869 Morin, Dexter, 422 Rodrigues, A. David, 1 143, 1163 Small, David S., 465 Patel, Nita J., 124 Morin, E., 988 Rodriguez, Lolita C., 615 Smallwood, R. A., 485 Paustenbach, Dennis J., 607 Moroni, Patricia, 160 Rojas, Katherine, 398 Smallwood, Richard A., 190 Payne, A. K., 497 Mounie, Jacques, 343 Romkes-Sparks, Marjorie, 473 Smith, Brian R., 1044 Pearce, Robin, 736 Mugford, Cheryl A., 290 Ronnenberg, William C., Jr., 60 Smith, Philip C., 566 Pearson, Paul 0., 383 Mulford, D. J., 765 Rose, James Q., 757 Some, William H., 548 Peggins, J. 0., 1, 18 Rose, Lucy M., 881 Somogyi, Andrew A., 334 Murray, Graeme I., 1274 Perotti, Beatrice Y. 1., 825 Rosebrough, Scott F., 1362 Sorrels, Shannon L., 271 Murry,DarylJ., 1110 Perret, G., 227 Mutlib, A. E., 951 Roy, Sandip K., 1394 Spaldin, Vanessa, 929 Perrin,John, 1117 Rozman, Elena, 976 Spielberg, Stephen P., 406 Peterson, Lisa, 749 Ruenitz, Peter C., 993 Sproles, G. Douglas, 806 Nadeau, Rosemary W., 904 Petitjean, 0., 227 Runciman, William B., 334 Sreerama, Lakshmaiah, 1080 Nagase, K., 28 Phillips, Diane L., 664 Runge-Morris, Melissa, 455 Stable, Paul L., 90 Nakagawa, Terumichi, 779 Phillips, L. R., 676 Rurak, Dan W., 1383 Stearns, Ralph A., 207, 266 Nakamura, Akio, 1268 Philpot, R. M., 1431 Rutten, Albert J., 334 Steenwyk, Rick C., 383 Nakano, Masayuki, 35 Pichard, Lydiane, 1253 Stem, Alan H., 607 Nakashima, Em, 1220 Pike, Victor W., 832 Sakuma, S., 28 Stevens, Douglas K., 1412 Nakatsu, Kanji, 1248 Pinaire, J. A., 642 Sallustio, Benedetta C., 892 Stoica, George, 854 Nardini, Denise, 713 Piquette-Miller, Micheline, 240 Salmona, M., 1 13 Streeter, Anthony J., 90 Narimatsu, Shizuo, 610, 999 Pitzenberger, Steven M., 185, 688 Sandberg, Jennifer A., 881 Streiff, Richard R., 1117 Nation, Roger L., 334 Placidi, Michel, 308 Sanders, Ruth A., 1094 Stresser, D. M., 965 Nau, Heinz, 887 Podoll, Terry, 490 Sass, J#{246}mOliver, 887 Strom, Stephen C., 415 Naylor, Jacky L., 102 Podval, Jordan, 736 Sastry, Sunita G., 1094 Strupczewski, J. T., 951 Neighbors, Suzanne M., 548 Pohland, Raymond C., 916 Sato, A., 28 Stuhler, John D., 757 Nellans, Hugh N., 149 Poklewska-Koziell, Margo, 1248 Sato, Yoshinobu, 1022 Stumpf, Walter E., 885 Nelson, Wendel L., 513 Pollack, Gary M., 478 Satoh, Hiroko, 904 Sugimoto, Tchihiro, 1268 Newton, Deborah J., 154 Poon, 0. K., 377 Satoh, Tetsuo, 1022 Sugiura, Munetoshi, 718 Ng, C. Y., 485 Poon, Karen, 255 Sauer, M. J., 501 Sukhai, Pratima, 590 Ngo, Leock Y., 525 Porter,Carl, 1117 Saurat, Jean-Hilaire, 887 Sun, He, 449 Nguyen, Ann C., 1099 Porthault, M., 227 Savrin, Jonathan E., 607 Sun, Jung-Hui, 600 Nichols, William K., 595 Potts, William, 799 Sawada, Yasufumi, 718 Supko, J. 0., 676 Nicolas, Florence, 308 Poulsen, L. L., 1390 Schaefer, William H., 1044 Surber, B. W., 765 Nicoll-Griffith, D., 1325 Powell, K. Leslie, 854 Scheide, Sallie, 904 Sutherland, Derek R., 724 Nicoll-Griffith, D. A., 65 Pritchard, J. Frederick, 90 Schepers, G., 143 Suzuki, Tokuji, 610, 999 Nicoll-Griffith, D. A., 1085 Prough, R. A., 642 Scherrmann, J. M., 1400 Svenson, Craig K., 295 Nijmeijer, S. M., 44 Prueksantanont, Thomayant, 688 Schiller, C. D., 1051 Swanson, Steven P., 916 Nijmeijer, Sandra M., 542 Schmid, Jochen, 1206 Sweeny, David J., 149 Nikula, K. J., 529 Qing, Wei-Guo, 854 Schmitz, Debra A., 201 Szumlanski, Carol, 398 Norton, Robin, 607 Schreier, Katherine M., 1 1 17 Szumlanski, Carol L., 854 Novak, R. F., 529 Radulovic, Louis L., 441 Schuetz, Em G., 415 Novak, Raymond F., 681, 818 Rahmani,R., 1051 Schwartz, Michael S., 185 Tacconi, M. T., 113 Nuss, Cindy, 671 Rahmani, Roger, 308 Segall, H. J., 422 Taguchi, Tadao, 1305 Nyarko, Alexander K., 107 Ramachandran, C., 65 Semple, Hugh A., 794 Takacs, Adrienne R., 90 AUTHOR INDEX 1439

Takahashii, Chikako, 999 Valles, B., 1051 Walsh, John S., 869 Worboys, Philip D., 393 Takeuchi, Masaharu, 35 Van Beijsterveldt, Ludy E. C., 216 Walter, B., 377 Wrighton, Steven A., 1037, 1231 Tam, Yun K., 525 Van Cantfort, Jacques, 1305 Wang, Jianyao, 1286 Wu, Dafang, 1297 Tanaka, Eiji, 48 Van Cauwenberghe, K., 433 Wang, Regina, 671 Wuyts, Koen, 216 Tang-Liu, Diane D-S., 708 Vandenbranden, Mark R., 1231 Wang, Regina W., 154 Wyss, R., 1051 Tanner, Richard J. N., 832 Vanderbeck, Scott M., 1291 Wang, Y. Karen, 615 Xia, Fangming, 794 Tarbit, M. H., 1225 Van Dyck, Dirk, 354 Wang, Ying, 60 Xiao, 0.-H., 642 Tarloff, Joan B., 290 Van Horn, Robert, 799 Ward, Alison, 473 Xu, Guihong, 1412 Tasaki, Takafumi, 1268 Van Houdt, Jos, 354 Ware, Joseph A., 295 Xu, Yuping, 846 Taylor, Wesley G., 1188 van Leengoed, L. A. M. G., 44 Waskiewicz, Mark J., 1291 Tebbett, Ian R., 664 Van Miert, A. S. J. P. A. M., 44 Watanabe, Kazuhito, 261 Yamaguchi, Yoshitaka, 1195 Tephly, Thomas R., 299 Van Miert, Adelbert S. J. P. A. M., Watanabe, Takashi, 1214 Yamamoto, Ikuo, 261 Terry, Christi M., 595 542 Waterhouse, Ian, 724 Yamamoto, Koujirou, 718 Theoharides, Anthony D., 688 Van Oosterom, A. T., 433 Waters, Stephen L., 832 Yamamoto, Yukio, 1268, 1301 Thdnot, Jean-Paul, 1253 Varga, Sandor L., 688 Watkins, John B., HI, 1094 Yamaoka, Kiyoshi, 779 Vastag, Kari J., 730 Thomas, Pascal, 308 Watkins, Paul B., 1315 Yamazaki, Hiroshi, 438 Vatsis, Kostas P., 1354 Thomas, Paul, 736 Weber, Wendell W., 1354 Yao,GuoWei, 1117 Thomas, Paul E., 1291 Vedres, Darrell D., 1188 Webster, Lorraine K., 363 Yashimura, Hidetoshi, 261 Thomas, S. B., 765 Veltman, James, 736 Wei, Xiaoxiong, 1335 Yasui, Hiroyuki, 779 Thompson, Wayne J., 185 Veltman, James C., 1094 Weimar, William R., 1117 Yergey, J., 1325 Thummel, Kenneth E., 490, 1426 Vento, Colleen, 455 Weinshilboum, Richard M., 398, Yergey, J. A., 65 Tod, M., 227 Ventresca, G. Pietro, 832 854 Yergey, J. A., 1085 Tokuma, Y., 28 Verheijden, J. H. M., 44 Werner, Michael, 861 Yeselwaram, K., 159 Touchi, Akira, 1195 Vermeulen, N. P. E., 667 White, Catherine A., 655 Yokel, Robert A., 1178 Trager, William F., 490, 659, 749 Vestal, Robert E., 1335 Wiebe, Leonard I., 223 Yost, Garold S., 595 Trenque, 1., 988 Vickers, Alison E. M., 321, 327 Yuen, Peter, 1426 Wieben, Eric D., 398 Trimble, L., 1325 Vickers, Stanley, 1007 Yukawa, Tadahiku, 35 Wiegand, Jan, 1117 Trimble, L. A., 65 Viger-Chougnet, A., 1051 Yun, Chul-Ho, 285 Wienkers, Larry C., 383 Trimble, L. A., 1085 Villa, P., 113 Tsuji, Akira, 1220 Vistelle, R., 988 Williams, D. E., 965 Zangar, R. C., 529 Tsuruda, Laurie S., 129 Vdlkel, H., 143 Williams, H., 1085 Zangar, Richard C., 681 TOrck, Dietrich, 441 Vollmer, K. Otto, 441 Williams, J. Andrew, 1274 Zeller, Klaus-Peter, 94 Twa, S. P., 1085 Voncken, P., 143 Wilson, Dennis W., 422 Zhang, Donglu, 1417 Tynes, Ronald E., 321 von Hodenberg, Albrecht, 441 Witkamp, R. F., 44 Zhang, Kanyin E., 1104 Vyas, Kamlesh P., 1104 Witkamp, Renger F., 542 Zhang, Xu-Jie, 1291 Uetrecht, Jack P., 246, 590 Woestenborghs, Robert, 354 Zhang, Zhiyi, 1339 Unadkat, Jashvant D., 473 Waidelich, Dietmar, 94 Woestenborghs, Robert J. H., 216 Zia-Amirhosseini, Parnian, 369, Urbanski, James J., 1028, 1044 Walle, Thomas, 506, 1286 Woodcroft, Kimberley J., 681 900 Usui, Takashi, 1214 Walle, U. Kristina, 506 Woodland, Joseph M., 910 Ziegler, D. M., 1390 SUBJECT INDEX

Abbot-66193, metabolism, liver cytochrome P450 enzymes involved in, hepatic microsomes and cytosols, species differences (humans, identification of (humans), 1163 rats, mice), 5 18 ABT-077, see Zileuton 8-Aminoquinoline ABT-418, in vitro hepatic metabolism, pattern of microsomal flavin- antiparasitic agents, metabolism, side-chain hydroxylation, 18 containing monooxygenase-dependent stereoselective N -oxidation WR 238605, metabolism, liver microsomes (rats), 1 (chimpanzees), 1143 5-Aminosalicylic acid, oxidation by hypochlorous acid to reactive imino- Acetaminophen quinone, possible role in treatment of inflammatory bowel dis- glutathione depletion kinetics, simulation study, 622 eases, 246 in vitro bioactivation, contribution of oxidation and deacetylation, liver Amitriptyline, biotransformation by Cunninghamella elegans, 1417 and kidney (rats), 290 Angiotensin II antagonist, GR117289, microbial biotransformation by sulfation and glucuronidation, cultured hepatocytes (humans), 303 Streptomyces rimosus to identify mammalian metabolite, 724 Acetylation Angiotensin H receptor antagonists, see DMP 81 1; Losartan role in mutagenicity of hydralazine, 559 Antibiotics, tiamulin, induction and inhibition of cytochrome P450 3A, slow, caused by labile and catalytically impaired mutant N- acetyltrans- studies in primary hepatocyte cultures and liver microsomes (pigs), ferase (mice), 1354 542 N-Acetylation, role in susceptibility to 2,3,5-(triglutathion-S-yl)hydroqui- Antibodies none-mediated nephrotoxicity, 1136 antipeptide, against overlapping sequences differentially inhibit Acetyl coenzyme A:arylamine N-acetyltransferase, comparison of activity CYP2D6 (humans), 671 in liver, kidney, and intestine (rats), 295 antipeptide, dog cytochrome P450 isozyme belonging to CYP2D sub- N-Acetyltransferase (NAT2 9), labile and catalytically impaired mutant, family, development (dogs), 1268 cause of slow acetylation (mice), 1354 antipeptide, targeted against specific regions of rat CYP2D1 and human Acidic drugs, peritoneal membrane transport, physiological pharmacoki- CYP2D6, 271 netic concepts, 1220 respiratory syncytial virus-specific reshaped monoclonal antibody Acitretin, elimination, rats pretreated with phenobarbital or (3- naphthofla- RSHZ19, preclinical pharmacokinetic evaluation, 1028 vone, 465 Anticonvulsant, novel, remacemide hydrochloride, induction of rodent Actinobacillus pleuropneumoniae, infection, suppression of oxidative he- hepatic drug-metabolizing enzyme activities, 922 patic drug metabolism and cytochrome P4503A mRNA levels Antiglaucoma medication, novel, prostaglandin derivative, ocular absorp- (pigs), 44 tion, distribution, and systemic absorption (rabbits), 35 Acyl glucuronides, ibuprofen and ibufenac, disposition and reactivity Antihypertensive agents, hydralazine, mutagenicity, role of acetylation, (monkeys, humans), 566 559 AL-1576, minimal effects on xenobiotic transformation, after subacute Antimalarial drugs topical-ocular dosing (rabbits), 1094 candidate, WR 238605, metabolism, liver microsomes (rats), 1 AL-41 14, minimal effects on xenobiotic transformation, after subacute formation of methemoglobin, improved pharmacodynamic model, 573 topical-ocular dosing (rabbits), 1094 Antimycotic agents, expression of microsomal epoxide hydrolase gene Albendazole, chiral sulfoxidation, liver microsomes (rats), 160 (rats), 460 Albumin, human serum Antineoplastic agent, investigational, perillyl alcohol, oral administration, disposition and reactivity of ibuprofen and ibufenac acyl glucuronides, pharmacokinetics of active drug metabolites (dogs), 676 in vitro, 566 Anti-opportunistic infection drugs, interaction with dapsone (humans), reactivity of tolmetin glucuronide with, identification of binding sites 473 and mechanisms of reaction, 369 Antiparasitic agents, 8-aminoquinoline, metabolism, side-chain hydroxy- stereoselective reversible binding properties of glucuronide conjugates lation, 18 of fenoprofen enantiomers to, 900 Antipeptide antibodies Alcohol (hydroxysteroid) sulfotransferase, and aryl sulfotransferase IV, against overlapping sequences differentially inhibit CYP2D6 (humans), intralobular localizations and distributions, enzyme- and sex-spe- 671 cific differences, liver (rats), 1346 dog cytochrome P450 isozyme belonging to CYP2D subfamily, devel- Aldehyde oxidase, role in in vitro conversion of famciclovir to penciclo- opment (dogs), 1268 vir, liver (humans), 251 targeted against specific regions of rat CYP2D1 and human CYP2D6, Aldehyde oxygenase, cytochrome P450-dependent, catalyzes oxidation of 271 tolualdehydes to toluic acids, liver (mouse), 261 Aralkyl sulfides, short-chain, (S)-sulfoxidation, selectivity of flavin-con- Aldehydes, catalyzed by liver flavin-containing monooxygenase, oxida- taming monooxygenase 5, 1431 tion (pigs), 1390 Arthritis, adjuvant, ketoprofen-treated and untreated, influence of severity ALDH-3, see Cytosolic class 3 aldehyde dehydrogenase of inflammation on disposition kinetics of propranolol enanti- Aldose reductase inhibitors, minimal effects on xenobiotic transformation, omers, 240 after subacute topical-ocular dosing (rabbits), 1094 Arylamine N-acetyltransferases, dapsone acetylation, liver (humans), 473 Alfentanil, metabolism, catalytic role of cytochrome P450 3A4, 490 Aryl sulfotransferase IV, and alcohol (hydroxysteroid) sulfotransferase, Amines, nonmacrolide, cytochrome P450 metabolic-intermediate com- intralobular localizations and distributions, enzyme- and sex-spe- plex formation, enhanced rates, rifampicin-treated liver micro- cific differences, liver (rats), 1346 somes (rabbits), 1379 Autoradiography, radioassay combined with, utility, tissue distribution Amino acids, interaction with propranolol, single-pass isolated, perfused studies and cytopharmacology, 885 liver (rats), 794 3 -Azido-3 -deoxythymidine 1-Aminobenzotriazole, N-aralkylated derivatives, inactivation of hepatic comparative metabolism, cultured hepatocytes (rats, dogs, monkeys, cytochromes P450 2B4 and 2B5, selectivity and kinetics (rabbits), humans), 308 577 lymphatic distribution (mice), 655 2-Amino-l-methyl-6-phenylimidazo[4,5-b}pyridine, biotransformation by 3 -Azido-2,3 -dideoxyuridine, lymphatic distribution (mice), 655 1440 SUBJECT INDEX 1441

Baculovirus, cDNA-directed expression of cytochrome P450 lAl (hu- and Hep 02 cells (rats, humans), 48 mans), 696 Chlorzoxazone 6-hydroxylation, selectivity of cytochrome P4502E1, 438 Benzoic acid glycine, conjugation, isolated perfused kidney (rats), 255 Chromium, screening, urine (letters to the editor), 607 O-Benzylguanine, pharmacokinetics and metabolism by liver microsomes CI-937, biotransformation, hepatocytes (rats), 94 (rats), 1394 Cicletamne, urinary excretion, stereochemical aspects (rats), 988 Benzyloxyresorufin, as specific substrate for cytochrome P450 2B 11 Cimetidine, effect on hepatic cytochrome P450, evidence for formation of (dogs), 1434 metabolite-intermediate complex, 1407 Biantrazole, two regioisomeric monocarboxylic acid metabolites excreted Ciprofibrate, enhanced expression of cytochrome P450 2El and 2B1/2B2, in urine (humans), 600 primary cultured hepatocytes (rats), 681 Bile Ciprofloxacin, disposition, isolated perfused liver (rats), 197 excretion of morphine-3-glucuronide (rats), 478 Clearance, drug, liver volume as determinant, children and adolescents, excretion of pyrrolic metabolites of [‘4C]monocrotaline (rats), 422 1110 excretion of verlukast, 1085 Clethrionomys rufocanus, wild, debrisoquine/sparteine-type polymorphic Biodistribution, 67Ga deferoxamineacetyl-cysteinylbiotin, 1362 drug metabolism, 1301 Bisphosphonate, YM175, pharmacokinetics (rats, dogs), 1214 Clofibric acid, glutathione conjugate, characterization and formation, 119 Biotransformation, amitriptyline, by Cunninghamella elegans, 1417 Cocaine, concentrations, blood and brain, increased with ethanol cotreat- Blood, cocaine concentrations, increased with ethanol cotreatment (mice), ment (mice), 664 664 Cotinine, accumulation, pigmented and unpigmented hair (rats), 143 Brain Cunninghamella elegans, biotransformation of amitriptyline, 1417 cocaine concentrations, increased with ethanol cotreatment (mice), 664 Cyclosporin derivative, see SDZ 1MM 125 cytochrome P450, levels, reassessment (rats), 651 Cyclosporin 0, metabolism (mice, rats, dogs), 615 nicotine metabolites, determination of, after peripheral radiolabeled Cysteine, infusion, in vivo modification of 3 -phosphoadenosine 5 - nicotine administration (rats), 1175 phosphosulfate and sulfate, 840 tetrahydrocannabinol metabolites, kinetics, effect of cannabidiol pre- Cytochrome P450 treatment (mice), 825 activities, hepatocytes in primary culture, effect of model inducers Breast cancer, patients on long-term therapy, identification of tamoxifen metabolites, 377 (humans), 553 Brimonidine, comparative ocular pharmacokinetics after single-dose ap- -catalyzed oxidation of (S)-nicotine, stereoselectivity and isotope ef- plication, albino and pigmented rabbits, 708 fects, 749 Bromodichloroacetate, metabolism (B6C3F1 mice), 1412 constitutive hepatic, inactivation by phencyclidine (rats), 201 Budesonide, metabolism by cytochrome P450 3A enzymes, liver (hu- -dependent aldehyde oxygenase, catalyzes oxidation of tolualdehydes to mans), 137 toluic acids, liver (mouse), 261 Bufuralol, regioselective and stereoselective oxidation, catalyzed by mi- -dependent monooxygenases, chiral sulfoxidation of albendazole, liver crosomes containing cDNA-expressed P4502D6 (humans), 513 microsomes (rats), 160 downregulation by polyinosinic acid-polycytidylic acid, influence of Caffeine, in vivo disposition, predicted from hepatic microsomal and duration of induction and species, 536 hepatocyte data, 349 enzymes Cannabidiol, pretreatment, effect on kinetics of tetrahydrocannabinol me- liver, involved in metabolism of zileuton and its N- dehydroxylated tabolites, brain (mice), 825 metabolite (humans), 1163 Carbamazepine, oxidative metabolites, covalent binding to neutrophils, responsible for sulfoxidation of S-methyl N,N- diethylthiolcarbam- 590 ate, identification of (humans, rats), 1153 Carbon tetrachloride, liver intoxication by, effect on hepatic local dispo- hepatic, effect of cimetidine, evidence for formation of metabolite- sition of oxacillin, 779 intermediate complex, 1407 Carboxylesterase human liver, oxidative metabolism of zolpidem, 1253 levels, liver microsomes, interindividual variation (humans), 1022 inhibitors, evaluation of specificities, in vitro metabolism of therapeutic nasal, induction following inhalation exposure to pyridine (rats), 529 agents, liver microsomes (humans), 154 Catechol-O-methyltransferase, induction in luminal epithelium of uterus induction, liver microsomes (monkeys), 736 by progesterone, inhibition by RU-486 (rats), 430 isoenzymes, metabolism of mofarotene, hepatocytes and liver micro- CCK-B antagonist, LY288513, 0-glucuronide metabolite, characteriza- somes, different species, 1051 tion and plasma levels (mice, rats, dogs), 910 isozymes CD4, recombinant human soluble, renal catabolism after intravenous dog, belonging to CYP2D subfamily, purification, characterization, administration (rats), 1044 and development of its antipeptide antibody, 1268 Chemopreventive agent, 2,6-dithiopurine, toxicity and metabolism (mice), inhibition and induction after repetitive administration of imipramine 854 Chiral sulfoxidation, albendazole, liver microsomes (rats), 160 (rats), 999 Chloride, intracellular, effect on cellular pharmacodynamics of cis-diam- “male-specific,” induction of, in female rats, by oxandrolone, 1291 minedichloroplatinum(II), 178 responsible for in vitro oxidative metabolism of finasteride, identifi- Chlorodifluoroethene, interaction with isoflurane, liver microsomes, role cation of (humans), 1126 of cytochrome P4502B6 in potentiation of haloethene metabolism levels, brain, reassessment (rats), 651 (humans), 60 metabolic-intermediate complex formation from nonmacrolide amines, Chloroethylamine, formation following ifosfamide administration (hu- enhanced rates, rifampicin-treated liver microsomes (rabbits), 1379 mans), 433 metabolism of tacrolimus in small intestine, 1315 2-Chloro-1,l,2-tetrafluoroethane, see HCFC-124 multiple forms, involved in metabolism of ondansetron (humans), 1225 l-Chloro-2,2,2-trifluoroethane, see HCFC133a structure, mechanism, and inhibition, 1181 S-(2-Chloro-1,1,2-trifluoroethyl)glutathione, biosynthesis, hepatocytes Cytochrome P450 lAl 1442 SUBJECT INDEX

activity, liver, inhibitors, relative potency of mexiletine, lidocaine, and induction and inhibition by tiamulin, primary hepatocyte cultures and tocainide (rats), 1335 liver microsomes (pigs), 542 cDNA-directed expression using baculovirus, purification, dependency mRNA levels, infection-mediated suppression (pigs), 44 on NADPH-P450 oxidoreductase, and reconstitution of catalytic subfamily members, role in biotransformation of losartan, liver micro- properties without purification (humans), 696 somes (humans), 207 expression in renal tissue, 3-methylcholanthrene and pyridine effects Cytochrome P450 3Al/2, role in sex-specific sulfoxidation of N- acetyl- (rats), 818 S-(pentachlorobutadienyl)-L-cysteine (rats), 861 R-warfarin metabolism as probe (humans), 1339 Cytochrome P450 3A4 Cytochrome P450 lA2 catalytic role, multiple pathways of alfentanil metabolism, 490 expression in renal tissue, 3-methylcholanthrene and pyridine effects metabolism of terfenadine, hepatic microsomes (humans), 631 (rats), 818 purified recombinant fusion protein containing, in vitro metabolism of hepatic, in vitro activity, determination, use of tacrine as isoenzyme- terfenadine, 765 role in formation of EXP3174, oxidation of losartan, liver microsomes specific probe (humans), 929 (humans), 285 R-warfarin metabolism as probe (humans), 1339 Cytochrome P450 PBD-21P450 2B 1 1, progesterone 21-hydroxylase ac- Cytochrome P450 2B 1 tivity, characterization through reconstitution, heterologous expres- liver, mechanism-based inactivation by phencycidine and iminium ion sion, and site-directed mutagenesis (dogs), 702 (rats), 786 Cytopharmacology, relevance, utility of radioassay combined with auto- xenobiotic-enhanced expression, primary cultured hepatocytes (rats), radiography, 885 681 Cytosol, metabolism of dichloroacetic acid, 1202 Cytochrome P450 2B2, xenobiotic-enhanced expression, primary cultured Cytosolic class 3 aldehyde dehydrogenase (ALDH-3), obtained from hepatocytes (rats), 681 tumor cells and normal tissue, human breast adenocarcinoma Cytochrome P450 2B4, inactivation by N-aralkylated derivatives of MCF-7/0 cells electroporated with, differential sensitivity to l-aminobenzotriazole, selectivity and kinetics (rabbits), 577 mafosfamide, 1080 Cytochrome P450 2B5, inactivation by N-aralkylated derivatives of 1-aminobenzotriazole, selectivity and kinetics (rabbits), 577 Dapsone, acetylation, liver arylamine N-acetyltransferases, and interac- Cytochrome P450 2B6, role in potentiation of haloethene metabolism, 60 tion with anti-opportunistic infection drugs (humans), 473 Cytochrome P450 2B 11 N-Deacetylation, role in susceptibility to 2,3,5-(triglutathion-S- yl)hydro- benzyloxyresorufin as specific substrate for (dogs), 1434 quinone-mediated nephrotoxicity, 1136 cytochrome P450 PBD-21P450 2B 1 1, progesterone 21-hydroxylase ac- Debrisoquine/sparteine-type polymorphic drug metabolism, wild Clethri- tivity, characterization through reconstitution, heterologous expres- onomys rufocanus, 1301 sion, and site-directed mutagenesis (dogs), 702 67Ga Deferoxamineacetyl-cysteinylbiotin, synthesis, pharmacokinetics, Cytochrome P450 2C, subfamily members and biodistribution, 1362 biotransformation of losartan, liver microsomes (humans), 207 Delta sleep-inducing peptide, transport and metabolism, cultured intestinal N4-hydroxylation of sulfamethoxazole, hepatic microsomes (rats, hu- epithelial cell monolayers (humans), 1372 mans), 406 DETC-Me, see S-Methyl N,N-diethylthiolcarbamate Cytochrome P450 2C11, in vitro metabolism of tirilazad mesylate (rats), Dexamethasone, induction of taxol metabolism (rats), 1286 383 Diabetes, streptozotocin-induced, effects on liver sulfotransferase gene Cytochrome P450 2D expression (rats), 455 isozymes, catalysis of 4-hydroxylation of methamphetamine enanti- cis-Diani.minedichloroplatinum(H), cellular pharmacodynamics, effect of intracellular chloride, 178 omers, 610 Dichloroacetic acid, metabolism in cytosol, 1202 subfamily, dog cytochrome P450 isozyme belonging to, purification, l,l-Dichloro-2,2-bis(p-chlorophenyl)ethane, control of cytotoxicity, oxi- characterization, and development of its antipeptide antibody, 1268 dation at C-l, lung cells (rabbits, humans), 595 Cytochrome P450 2D1, antipeptide antibodies targeted against specific N-(3,5-Dichlorophenyl)succinimide, metabolism, isolated hepatocytes regions (rats), 271 (rats), 107 Cytochrome P450 2D6 [‘4C]- and [35S]S-(l,2-Dichlorovinyl)-L-cysteine, metabolism (rats), 124 antipeptide antibodies against overlapping sequences differentially in- 2 , 3 -Dideoxycytidine, placental transfer and fetal disposition (monkeys), hibit (humans), 671 881 antipeptide antibodies targeted against specific regions (humans), 271 2 , 3 -Dideoxyinosine, placental transfer and fetal disposition (monkeys), cDNA-expressed, microsomes containing, catalytic role, regioselective 881 and stereoselective oxidation of metoprolol and bufuralol (hu- N,N-Diethylbenzamide, metabolites, detection in urine, NMR spectros- mans), 513 copy (rats), 1188 -dependent oxidation of GBR 12909, computer prediction and experi- Diethyl ether, lack of residual effects on lidocaine metabolism, single-pass mental validation, 667 isolated liver perfusion system (rats), 525 Cytochrome P450 2El N’,N’ ‘-Diethylnorspermine, metabolism and pharmacokinetics, 1117 liver, stereoselective metabolism of enflurane (humans), 1426 5,6-Dimethylxanthenone-4-acetic acid, metabolism and elimination, iso- selectivity, chlorzoxazone 6-hydroxylation, 438 lated perfused liver (rats), 363 xenobiotic-enhanced expression, primary cultured hepatocytes (rats), [‘4C]1,3-Dinitrobenzene, metabolism by small intestine mucosa in vitro 681 (rats), 982 Cytochrome P450 3A 6,8-Dioxabicyclo[3.2.l}octanyl moiety, role in microsomal metabolism of biotransformation of SDZ 1MM 125, liver (humans), 321 5-lipoxygenase inhibitors, 1325 enzymes, metabolism of budesonide, liver (humans), 137 Disulfiram, bioactivation, terminal step, 1153 induction, hepatocyte primary cultures, comparative analysis (rats, rab- 2,6-Dithiopurine, toxicity and metabolism (mice), 854 bits, humans), 415 DMP 811 (L-708,404), disposition (rats, monkeys, chimpanzees), 1 104 SUBJECT INDEX 1443

Dolasetron mesylate, metabolism (humans), 806 GBR 12909, oxidation, cytochrome P4502D6-dependent, computer pre- DuP 734, pharmacokinetics and presystemic first-pass elimination (rats), diction and experimental validation, 667 603 Gemfibrozil, l-O-13-acyl glucuronide, reactivity, pharmacokinetics of co-

DuP 941 , two regioisomeric monocarboxylic acid metabolites excreted in valently bound gemfibrozil-protein adducts (rats), 892 urine (humans), 600 “Gender,” use of term as synonym for sex (letter to the editor), 1007 Glucuronidation, naftazone, liver microsomes (humans, rats), 1305 Ebrotidine, metabolism, urine, investigation by liquid chromatography- Glucuronides atmospheric pressure chemical ionization mass spectrometry (hu- acyl glucuronide, gemfibrozil, reactivity (rats), 892 mans), 976 acyl glucuronides, ibuprofen and ibufenac, disposition and reactivity Enflurane, stereoselective metabolism, liver cytochrome P450 2E1 (hu- (monkeys, humans), 566 mans), 1426 conjugate of flucytosine, structural determination (humans), 813 Enzymes, hepatic, activities, phase I and phase II in vitro, comparison conjugates of fenoprofen enantiomers, stereoselective reversible bind- (humans, dogs, rhesus monkeys, cynomolgus monkeys), 1231 ing properties to human serum albumin, 900 Epoxide hydrolase gene, microsomal, differential expression by imidazole 0-glucuronide, metabolite of LY288513, characterization and plasma and triazole antimycotic agents (rats), 460 levels (mice, rats, dogs), 910 ET18-OMe, fate in malignant cells, normal cells, and isolated and per- phenobarbital N-glucuronides, urinary metabolites of phenobarbital fused rat liver, 113 (mice), 548 Ethanol, cotreatment with, increased blood and brain cocaine concentra- quaternary ammonium-linked, formation, expressed human UGT1 .4 tions (mice), 664 protein catalyzes, 299 Ethoxycoumarin, rates of oxidation, liver slices (rats), 393 Glutathione 7-Ethoxycoumarin, improved HPLC assay for assessment of liver slice conjugate of clofibric acid, characterization and formation, 119 metabolic viability, 869 -dependent metabolism of trichloroethylene, isolated liver and kidney N-Ethylbenzamide, metabolites, detection in urine, NMR spectroscopy cells, role in mitochondrial and cellular toxicity (rats), 846 (rats), 1188 depletion kinetics with acetaminophen, simulation study, 622 5-Ethyl-2 -deoxyuridine formation of conjugates, biotransformation of CI-937, hepatocytes novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs, pharmacoki- (rats), 94 netics and bioavailability (mice), 223 verlukast conjugation with, liver and kidney cytosols (rats), 1085 pharmacokinetics and bioavailability (mice), 223 Glyceryl trmnitrate, vasodilation induced by, mechanism of action and EXP3174, formation, role of cytochrome P4503A(4), oxidation of losar- formation of nitric-oxide adduct, 1248 tan, liver microsomes (humans), 285 GR117289, microbial biotransformation by Streptomyces rimosus to iden- Eyes tify mammalian metabolite, 724 antiglaucoma medication, novel, prostaglandin derivative, ocular ab- sorption, distribution, and systemic absorption (rabbits), 35 Haloethene, metabolism, potentiation, role of cytochrome P4502B6, 60 brimonidine, comparative ocular pharmacokinetics after single- dose HCFC-124, gas-uptake pharmacokinetics and metabolism (rats, mice, application, albino and pigmented rabbits, 708 hamsters), 875 F(ab)2, immunoglobulin 0, and Fab fragment uptake kinetics, isolated HCFC133a, fluorine-containing metabolites, identification and quantifi- perfused liver and hepatic cells (rats), 1400 cation (rats), 102 Famciclovir, in vitro conversion to penciclovir, role of aldehyde oxidase, Hep G2 cells, biosynthesis of S-(2-chloro-l,l,2- trifluoroethyl)glutathione liver (humans), 251 (rats, humans), 48 Fenoprofen, enantiomers, glucuronide conjugates, stereoselective revers- Hepatic enzymes, activities, phase I and phase II in vitro, comparison ible binding properties to human serum albumin, 900 (humans, dogs, rhesus monkeys, cynomolgus monkeys), 1231 Finasteride, in vitro oxidative metabolism, identification of human cyto- Hepatocytes chrome P450 isozymes responsible for, 1126 biosynthesis of S-(2-chloro-l,l,2-trifluoroethyl)glutathione (rats, hu- FK506, see Tacrolimus mans), 48 Flavin biotransformation of CI-937 (rats), 94 adenine dinucleotide-containing and cytochrome P450-dependent mo- cultured, comparative metabolism of 3 -azido-3 -deoxythymidine (rats, nooxygenases, chiral sulfoxidation of albendazole, liver micro- dogs, monkeys, humans), 308 somes (rats), 160 cultured, regulation of Ah gene battery via Ah receptor-dependent and -containing monooxygenase, liver, oxidation of aldehydes catalyzed by independent processes (rats), 642 (pigs), 1390 cultured, sulfation and glucuronidation of acetaminophen (humans), -containing monooxygenase 5, selectivity for (S)-sulfoxidation of short- 303 chain aralkyl sulfides, 1431 data, prediction of in vivo disposition of caffeine, 349 -containing monooxygenase-dependent stereoselective N -oxidation, N-(3,5-dichlorophenyl)succinimide metabolism (rats), 107 microsomal, unique pattern, in vitro hepatic metabolism of ABT- isolated, and precision-cut liver slices, quantitative differences in phase 418 (chimpanzees), 1143 I and II metabolism (rats), 1274 Flucytosine, glucuronide conjugate, structural determination (humans), mofarotene metabolism, different species, comparison with in vivo data 813 and evaluation of cytochrome P450 isoenzymes involved in human Flurbiprofen, enantiomers, in vitro glucuronidation, characterization, 343 biotransformation, 1051 Free radical scavenger, MDL 74,405, disposition and cardioselectivity primary culture, cytochrome P450 activities, effect of model inducers after intravenous infusion (rats, dogs), 757 (humans), 553 primary cultured, xenobiotic-enhanced expression of cytochrome P450 Gabapentin, disposition (mice, rats, dogs, monkeys), 441 2E1 and 2Bl/2B2 (rats), 681 Ganciclovir, double prodrug, metabolism and pharmacokinetics (rats, primary cultures, cytochrome P4503A induction, comparative analysis monkeys), 1242 (rats, rabbits, humans), 415 1444 SUBJECT INDEX

primary cultures, cytochrome P4503A induction and inhibition by cultured epithelial cell monolayers, transport and metabolism of delta tiamulin (pigs), 542 sleep-inducing peptide (humans), 1372 Hexachlorobutadiene metabolite, N-acetyl-S-(pentachlorobutadienyl)- L- sites of biotransformation for SDZ 1MM 25 (humans), 327 cysteine, sex-specific sulfoxidation, role ofcytochrome P4503A1/2 Intestine, small, see Small intestine (rats), 861 Iron, overload, effect on metabolism and urinary recovery of 3- hydroxy- HFA134a, inhaled, disposition, healthy subjects and patients with chronic pyridin-4-one chelating agents (rats), 314 airflow limitation, 832 Isoflurane, interaction with chlorodifluoroethene, liver microsomes, role HIV- 1 protease inhibitors of cytochrome P4502B6 in potentiation of haloethene metabolism L-689,502, metabolism, liver slices (rats), 185 (humans), 60 L-735,524, metabolites, urine (humans), 266 L-735,524, pH-dependent oral absorption (rats, dogs), 730 Jacobine, susceptibility of guinea pig to, major factors for, 1263 SK&F 107461, metabolites, characterization using liquid chromatogra- phy/mass spectrometry (rats), 799 Ketoprofen, -treated adjuvant arthritis, severity of inflammation, influence HIV-l reverse Iranscriptase inhibitor, L-738,372, metabolism, species on disposition kinetics of propranolol enantiomers, 240 differences, in vitro and in vivo studies (rats, dogs, monkeys, Kidney humans), 688 acetyl coenzyme A:arylamine N-acetyltransferase activity (rats), 295 HPLC assay, improved, for assessment of liver slice metabolic viability benzoic acid glycine conjugation (rats), 255 using 7-ethoxycoumarmn, 869 bioactivation of acetaminophen, in vitro, contribution of oxidation and 5-HI3 receptor antagonist, dolasetron mesylate, metabolism (humans), deacetylation (rats), 290 806 catabolism of recombinant human soluble CD4, after intravenous ad- Hydralazine, mutagenicity, role of acetylation, 559 ministration (rats), 1044 Hydroxylamine, formation and reduction, role of cytochrome P4502C CYP1A1 and CYPIA2 expression, 3-methylcholanthrene and pyridine subfamily, hepatic microsomes (rats, humans), 406 effects (rats), 818 3-Hydroxypyridin-4-one chelating agents cytosols, verlukast conjugation with glutathione (rats), 1085 metabolism and urinary recovery, effect of iron overload (rats), 314 importance of, disposition of morphine-3-glucuronide, intravenous in- orally active, bioavailability and disposition, influence of lipophilicity, fusions (sheep), 334 1178 isolated cells, glutathione-dependent metabolism of trichloroethylene, Hypochlorous acid, oxidation of 5-aminosalicylic acid to reactive imino- role in mitochondrial and cellular toxicity (rats), 846 quinone, possible role in treatment of inflammatory bowel dis- nephrotoxicity, 2,3,5-(triglutathion-S-yl)hydroquinone-mediated, spe- eases, 246 cies susceptibility to, metabolism as determinant, role of N- acety- Ibufenac, acyl glucuronides, disposition and reactivity, comparison with lation and N-deacetylation, 1 136 ibuprofen (monkeys, humans), 566 sites of biotransformation for SDZ 1MM 25 (humans), 327 Ibuprofen, acyl glucuronides, disposition and reactivity, comparison with ibufenac (monkeys, humans), 566 L-689,502, metabolism, liver slices (rats), 185 Ifosfamide, administration, formation of chloroethylamine and 1 ,3- ox- L-702,539, in vivo and in vitro biotransformations, 65 azolidine-2-one (humans), 433 L-708,404, disposition (rats, monkeys, chimpanzees), 1 104 Iloperidone, in vitro and in vivo metabolites, rapid identification, appli- L-735,524 cation of hyphenated LCINMR and LCIMS techniques, 951 metabolites, urine (humans), 266 Imidazole, expression of microsomal epoxide hydrolase gene (rats), 460 pH-dependent oral absorption (rats, dogs), 730 Imidocarb, residues in edible bovine tissues and in vitro assessment of L-738,372, metabolism, species differences, in vitro and in vivo studies metabolism and cytotoxicity, 501 (rats, dogs, monkeys, humans), 688 Iminium ion, mechanism-based inactivation of liver cytochrome P4502B 1 L-739,010, microsomal metabolism to reactive intermediates that co- (rats), 786 valently bind to protein, role of 6,8-dioxabicyclo[3.2.l]octanyl Iminoquinone, reactive, oxidation of 5-aminosalicylic acid, possible role moiety, 1325 in treatment of inflammatory bowel diseases, 246 L-746,530, microsomal metabolism to reactive intermediates that co- Imipramine, repetitive administration, inhibition and induction of cyto- valently bind to protein, role of 6,8-dioxabicyclo[3.2.l]octanyl chrome P450 isozymes (rats), 999 moiety, 1325 Immunoglobulin 0, F(ab )2’ and Fab fragment uptake kinetics, isolated Lansoprazole, and omeprazole, comparative pharmacokinetic/pharmaco- perfused liver and hepatic cells (rats), 1400 dynamic study (rats), 718 Immunosuppressants, see Tacrolimus Lauric acid hydroxylase activities, liver (humans), 1037 Indole-3-carbinol, mechanisms of tumor modulation, disposition and ex- LC/NMR and LCIMS techniques, application, rapid identification of in cretion (rats), 965 vitro and in vivo metabolites of iloperidone, 951 Infection, -mediated suppression of oxidative hepatic drug metabolism Lidocaine and cytochrome mRNA levels (pigs), 44 as inhibitor of liver CYP1A1 activity, relative potency (rats), 1335 Inflammatory bowel diseases, treatment, possible role of oxidation of metabolism, lack of residual effects of diethyl ether, methoxyflurane, 5-aminosalicylic acid to reactive iminoquinone, 246 and sodium pentobarbital, single-pass isolated liver perfusion sys- Interferon inducer, polyinosinic acid-polycytidylic acid, downregulation tern (rats), 525 of cytochrome P450, influence of duration of induction and spe- Lipophilicity, influence on bioavailability and disposition of orally active cies, 536 3-hydroxypyridin-4-one metal chelators, 1178 Interleukin-2, recombinant human, comparison of mass balance, pharma- Lipoxygenase inhibitors, microsornal metabolism to reactive interrnedi- cokinetics, and disposition (monkeys), 904 ates that covalently bind to protein, role of 6,8-dioxabi- Intestine cyclo[3.2.l]octanyl moiety, 1325 acetyl coenzyme A:arylamine N-acetyltransferase activity (rats), 295 Liver contribution to presystemic elimination of morphine (rabbits), 584 acetyl coenzyrne A:arylamine N-acetyltransferase activity (rats), 295 SUBJECT INDEX 1445

bioactivation of acetaminophen, in vitro, contribution of oxidation and Losartan deacetylation (rats), 290 biotransformation to active carboxylic acid metabolite, liver micro- chiral sulfoxidation of albendazole (rats), 160 somes (humans), 207 contribution to presystemic elimination of morphine (rabbits), 584 oxidation, role of cytochrome P450 3A(4) in formation of EXP3 174, conversion of famciclovir to penciclovir, role of aldehyde oxidase liver microsomes (humans), 285 (humans), 251 Losoxantrone, two regioisomeric monocarboxylic acid metabolites ex- cytochrome P4503A induction and inhibition by tiamulin (pigs), 542 creted in urine (humans), 600 cytosols, verlukast conjugation with glutathione (rats), 1085 Lungs disposition of ciprofloxacin (rats), 197 cells, oxidation at C-l, control of l,1-dichloro-2,2-bis(p- chlorophe- flavin-containing monooxygenase, oxidation of aldehydes catalyzed by nyl)ethane cytotoxicity (rabbits, humans), 595 (pigs), 1390 contribution to presystemic elimination of morphine (rabbits), 584 intoxication by carbon tetrachloride, effect on hepatic local disposition LY255582, disposition (rats, dogs), 916 of oxacillin, 779 LY2885 13, 0-glucuronide metabolite, characterization and plasma levels isolated cells, glutathione-dependent metabolism of trichloroethylene, (mice, rats, dogs), 910 role in mitochondrial and cellular toxicity (rats), 846 Mafosfamide, human breast adenocarcinoma MCF-7/0 cells electropo- kinetics of drug metabolism, examples of high- and low-clearance rated with cytosolic class 3 aldehyde dehydrogenases obtained compounds (rats), 393 from tumor cells and normal tissue, differential sensitivity, 1080 lauric acid hydroxylase activities (humans), 1037 cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]- metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid platinum(II), pharmacokinetics, tissue distribution, and excretion (rats), 363 (dogs), 1280 metabolism of ABT-41 8, pattern of microsomal flavin-containing mo- MDL 74,405, disposition and cardioselectivity after intravenous infusion nooxygenase-dependent stereoselective N -oxidation (chimpan- (rats, dogs), 757 zees), 1143 Meloxicam, pharmacokinetics and metabolic pattern, after intravenous metabolism of budesonide by cytochrome P450 3A enzymes (humans), infusion and oral administration, healthy subjects, 1206 137 Metabolic-intermediate complex, formation from nonmacrolide amines, metabolism of [‘4C]naphthalene, 129 cytochrome P450, enhanced rates, rifampicin-treated liver micro- metabolism of propranolol, fetal (sheep), 190 somes (rabbits), 1379 metabolism studies, microdialysis sampling, impact on liver tissue, Metabolite-intermediate complex, formation, evidence, effect of cimeti- 1072 dine on hepatic cytochrome P450, 1407 oxidation of tolualdehydes to toluic acids, catalyzed by cytochrome Methamphetamine, enantiomers, 4-hydroxylation, catalysis by cyto- P450-dependent aldehyde oxygenase (mice), 261 chrome P4502D isozymes, 610 oxygenation, effects of chronic left ventricular failure (rats), 485 Methemoglobin, formation by antimalarial drugs, improved pharmacody- sites of biotransformation for SDZ 1MM 25 (humans), 327 namic model, 573 slices, precision-cut, and isolated hepatocytes, quantitative differences Methionine, infusion, in vivo modification of 3 -phosphoadenosine 5 in phase I and II metabolism (rats), 1274 -phosphosulfate and sulfate, 840 volume, as determinant of drug clearance, children and adolescents, Methoxyflurane, lack of residual effects on lidocaine metabolism, single- 1110 pass isolated liver perfusion system (rats), 525 Liver microsomes 3-Methylcholanthrene, effects on CYP1A1 and CYPIA2 expression, renal carboxylesterase levels, interindividual variation (humans), 1022 tissue (rats), 818 cytochrome P450 inhibitors, in vitro metabolism of therapeutic agents, S-Methyl N,N-diethylthiolcarbamate, sulfoxidation, identification of P450 evaluation of specificities (humans), 154 enzymes responsible for (humans, rats), 1 153 induction of cytochrome P450 (monkeys), 736 Metoprolol, regioselective and stereoselective oxidation, catalyzed by isoflurane-chlorodifluoroethene interaction, role of cytochrome microsomes containing cDNA-expressed P4502D6 (humans), 513 P4502B6 in potentiation of haloethene metabolism (humans), 60 Mexiletine, as inhibitor of liver CYP1A1 activity, relative potency (rats), metabolism of O-benzylguanine (rats), 1394 1335 mofarotene metabolism, different species, comparison with in vivo data Microdialysis sampling, hepatic metabolism studies, probe design and and evaluation of cytochrome P450 isoenzymes involved in human implantation technique, impact on liver tissue, 1072 biotransformation, 1051 MK-0679, see Verlukast oxidation of losartan, role of cytochrome P4503A(4) in formation of Mofarotene, metabolism in hepatocytes and liver microsomes, different EXP3174 (humans), 285 species, comparison with in vivo data and evaluation of cyto- reduction and glucuronidation of naftazone (humans, rats), 1305 chrome P450 isoenzymes involved in human biotransformation, rifampicin-treated, cytochrome P450 metabolic-intermediate complex 1051 formation from nonmacrolide amines, enhanced rates (rabbits), [‘4CjMonocrotaline, pyrrolic metabolites, biliary excretion (rats), 422 1379 Monooxygenase stereoselective glucuronidation of zileuton isomers (humans), 149 activities, brain cytochrome P450, reassessment (rats), 651 verapamil-infused isolated, input rate-dependent stereoselective phar- -dependent stereoselective N -oxidation, microsomal flavin- containing, macokinetics (rats), 637 unique pattern, in vitro hepatic metabolism of ABT-418 (chimpan- WR 238605 metabolism (rats), 1 zees), 1143 Loperamide flavin adenine dinucleotide-containing and cytochrome P450- depen- gastrointestinal distribution (dogs), 216 dent, chiral sulfoxidation of albendazole, liver microsomes (rats), reduction of loperamide oxide, gut (rats, dogs, humans), 354 160 Loperamide oxide flavin-containing, liver, oxidation of aldehydes catalyzed by (pigs), gastrointestinal distribution (dogs), 216 1390 reduction to loperamide, gut (rats, dogs, humans), 354 Monooxygenase 5, flavin-containing, selectivity for (S)- sulfoxidation of 1446 SUBJECT INDEX

short-chain aralkyl sulfides, 1431 Oxidative hepatic drug metabolism, infection-mediated suppression Morphine (pigs), 44 comparative disposition during separate intravenous infusions of mor- “Oxygenation,” use of term as synonym for oxidation (letter to the editor), phine and morphine-3-glucuronide, importance of kidney (sheep), 1007 334 presystemic elimination, contribution of intestine, liver, and lungs (rab- Pacitaxel, see Taxol bits), 584 Paraoxonases, purified serum, comparison (humans, rabbits), 935 Morphine-3-glucuronide Penciclovir, in vitro conversion of famciclovir to, role of aldehyde oxi- biliary excretion and enterohepatic recirculation (rats), 478 dase, liver (humans), 251 comparative disposition during separate intravenous infusions of mor- Perillyl alcohol, oral administration, pharmacokinetics of active drug phine and morphine-3-glucuronide, importance of kidney (sheep), metabolites (dogs), 676 334 Peritoneal membrane transport, acidic drugs, physiological pharmacoki- 3-Morpholinosydnonimine, vasodilation induced by, nitric oxide forma- netic concepts, 1220 tion concurrent with, time-dependent increase, 1248 Peroxisomal a-oxidation, and metabolic pathway of (+)-S-l45, 1195 Pharmacogenetics, thiopurine methyltransferase, cloning of human liver

NADPH-P450 cDNA and processed pseudogene on human chromosome 18q21 . I, oxidoreductase, dependency on, cDNA-directed expression of cyto- 398 chrome P450 lAl using baculovirus (humans), 696 Pharmacokinetics, species similarities and differences, 1008 reductase, purified recombinant fusion protein containing, in vitro me- Phencyclidine tabolism of terfenadine, 765 inactivation of constitutive hepatic cytochromes P450 (rats), 201 Naftazone, reduction and glucuronidation, liver microsomes (humans, mechanism-based inactivation of liver cytochrome P4502B1 (rats), 786 rats), 1305 Phenobarbital [‘4C]Naphthalene, metabolism in B6C3F, murine isolated perfused liver, -inducible dog liver cytochrome P450, major, benzyloxyresorufin as 129 specific substrate for, 1434 Naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539, in vivo pretreatment with, acitretin elimination (rats), 465 and in vitro biotransformations, 65 urinary metabolites, phenobarbital N-glucuronides (mice), 548 j3-Naphthoflavone, rats pretreated with, acitretin elimination, 465 Phenobarbital N-glucuronides, urinary metabolites of phenobarbital Naproxen glucuronide, stereoselective disposition (rats), 1099 (mice), 548 Nephrotoxicant, N-(3,5-dichlorophenyl)succinimide, metabolism, isolated Phenol sulfotransferase, monoamine-sulfating form, bacterial expression hepatocytes (rats), 107 and kinetic characterization (humans), 945 Neurontin, disposition (mice, rats, dogs, monkeys), 441 3 -Phosphoadenosine 5 -phosphosulfate, in vivo modification by infusion Nicotine of sodium sulfate, cysteine, and methionine, 840 accumulation, pigmented and unpigmented hair (rats), 143 Phosphodiester bond, rapid plasma clearance and metabolism in vitro of metabolites, in brain, after peripheral radiolabeled nicotine administra- phosphorothioate oligodeoxynucleotide, 1297 tion, detection of nornicotine (rats), 1175 Phosphodiester oligodeoxynucleotide, pharmacokinetics and organ clear- (S)-Nicotine, cytochrome P450-catalyzed oxidation, stereoselectivity and ance, 55 isotope effects, 749 Phosphorothioate oligodeoxynucleotide, rapid plasma clearance and me- S-Nitroso-N-acetylpenicillamine, vasodilation induced by, nitric oxide tabolism in vitro with phosphodiester bond, 1297 formation concurrent with, time-dependent increase, 1248 Polyinosinic acid-polycytidylic acid, downregulation of cytochrome P450, NMR spectroscopy, detection of metabolites of N-ethylbenzamide and influence of duration of induction and species, 536 N,N-diethylbenzamide, urine (rats), 1188 Primaquine, metabolism, side-chain hydroxylation, 18 Nonmacrolide amines, cytochrome P450 metabolic-intermediate complex Progesterone formation, enhanced rates, rifampicin-treated liver microsomes 21-hydroxylase activity, cytochrome P450 PBD-21P450 2B 1 1, charac- (rabbits), 1379 terization through reconstitution, heterologous expression, and site- Nornicotine, detection of, after peripheral radiolabeled nicotine adminis- directed mutagenesis (dogs), 702 tration (rats), 1175 induction of catechol-O-methyltransferase in luminal epithelium of uterus, inhibition by RU-486 (rats), 430 1-O-Octadecyl-2-O-methyl-rac-glycero-3-phosphocoline, see ET18-OMe Propranolol Omeprazole, and lansoprazole, comparative pharmacokinetic/pharmaco- enantiomers, disposition kinetics in ketoprofen-treated and untreated dynamic study (rats), 718 adjuvant arthritis, influence of severity of inflammation, 240 Ondansetron, metabolism, multiple forms of cytochrome P450 involved in first-pass uptake and systemic clearance, contribution of small intestine (humans), 1225 (rabbits), 279 Opioid antagonist, LY255582, disposition (rats, dogs), 916 fetal hepatic metabolism (sheep), 190 Oxacillin, hepatic local disposition, effect of liver intoxication by carbon interaction with amino acids, single-pass isolated, perfused liver (rats), tetrachloride, 779 794 Oxazepam, metabolism and elimination (F344 rats), 232 Prostaglandin derivative, ocular absorption, distribution, and systemic 1,3-Oxazolidine-2-one, formation following ifosfamide administration absorption (rabbits), 35 (humans), 433 Proton pump inhibitors, omeprazole and lansoprazole, comparative phar- Oxandrolone, induction of “male-specific” cytochrome P450 isozymes macokinetic/pharmacodynamic study (rats), 718 (female rats), 1291 Pyridine Oxidation, use of “oxygenation” as synonym for (letter to the editor), 1007 effects on CYP1A1 and CYP1A2 expression, renal tissue (rats), 818 N -Oxidation, stereoselective, microsomal flavin-containing monooxyge- enhanced expression of cytochrome P450 2E1 and 2B1/2B2, primary nase-dependent, unique pattern, metabolism of ABT-418 (chim- cultured hepatocytes (rats), 681 panzees), 1143 inhalation exposure, induction of nasal carboxylesterase (rats), 529 SUBJECT INDEX 1447

Pyrrolizidine alkaloids, jacobine, susceptibility of guinea pig to, major Sodium nitroprusside, vasodilation induced by, nitric oxide formation factors, 1263 concurrent with, time-dependent increase, 1248 Sodium pentobarbital, lack of residual effects on lidocaine metabolism, Radioassay combined with autoradiography, utility, tissue distribution single-pass isolated liver perfusion system (rats), 525

studies and cytopharmacology, 885 Sodium sulfate, infusion, in vivo modification of 3 - phosphoadenosine 5 Recombinant human interleukin-2, comparison of mass balance, pharma- -phosphosulfate and sulfate, 840 cokinetics, and disposition (monkeys), 904 Spectroscopy, NMR, detection of metabolites of N-ethylbenzamide and Recombinant human soluble CD4, renal catabolism after intravenous N,N-diethylbenzamide, urine (rats), 1188 administration (rats), 1044 Streptomyces rimosus, microbial biotransformation of GR1 17289 to iden- 4-5a-Reductase, in vitro metabolism of tirilazad mesylate (rats), 383 tify mammalian metabolite, 724 Respiratory syncytial virus-specific reshaped monoclonal antibody Streptozotocin, -induced diabetes, effects on liver sulfotransferase gene RSHZ19, preclinical pharmacokinetic evaluation, 1028 expression (rats), 455 Retinoic acid Sulfamethoxazole, N4-hydroxylation by cytochrome P450, hepatic micro- all-trans- somes (rats, humans), 406 isomerization and metabolism, and dysmorphogenic effects on em- Sulfate, in vivo modification by infusion of sodium sulfate, cysteine, and bryos during neurulation, 1058 methionine, 840 time- and dose-dependent kinetics, oral or intravenous administration Sulfinpyrazone, and metabolites, inhibition of (S)-warfarin metabolism, (rats), 227 659 9-cis- Sulfotransferase, liver gene expression, effects of streptozotocin- induced isomerization and metabolism, and dysmorphogenic effects on em- diabetes (rats), 406 bryos during neurulation, 1058 (S)-Sulfoxidation, short-chain aralkyl sulfides, selectivity of flavin-con- oral, metabolism, identification of 9-cis-retinoyl-f3- glucuronide and taming monooxygenase 5, 1431 9-cis-4-oxo-retinoy1-3-glucurothde as urinary metabolites (hu- Sustained-release preparation, in vivo drug release rate constant, method mans), 887 of determining, 449 Retinoid metabolism, embryonic, model system for study of, Xenopus laevis Tacrine, use as isoenzyme-specific probe, determination of hepatic cyto- isomerization and metabolism of all-trans-retinoic acid and 9- cis reti- chrome P4501A2 activity (humans), 929 noic acid, and dysmorphogenic effects on embryos during neuru- Tacrolimus (FK506) lation, 1058 metabolism, identification and biological activities of metabolites oxi- metabolism of 9-cis- and all-trans-retinals and retinols to their cone- dized at multiple sites, 28 sponding acid forms, 72 metabolism, small intestine, cytochrome P450, drug interactions, and metabolism of aJl-trans-3,4-didehydroretinol to all-trans-3,4- didehy- interindividual variability, 1315 droretinoic acid, 83 Tamoxifen Rifampicin, -treated liver microsomes, cytochrome P450 metabolic- in- acidic metabolites, aspects of formation and fate (female rats), 993 termediate complex formation from nonmacrolide amines, en- metabolites, identification in human HEP 02 cell line, human liver hanced rates (rabbits), 1379 homogenate, and patients on long-term therapy for breast cancer, RU-486, inhibition of induction of catechol-O-methyltransferase in lumi- 377 nal epithelium of uterus by progesterone (rats), 430 Taxol metabolism, dexamethasone induction of (rats), 1286 (+)-S-l45, metabolic pathway, in vitro studies, evidence for two meta- metabolism and disposition, cancer patients, 506 bolic pathways in peroxisomal /3-oxidation (rats), 1195 plasma and tissue disposition after intraperitoneal administration Scientific writing, use of “causalisms” (letter to the editor), 1 107 (mice), 713 SDZ 1MM 125 Terfenadine liver cytochrome P4503A biotransformation (humans), 321 in vitro metabolism by purified recombinant fusion protein containing sites for biotransformation, liver and kidney slices and intestine (hu- cytochrome P4503A4 and NADPH-P450 reductase, 765 mans), comparison with rat liver slices and cyclosporin A metab- metabolism associated with CYP3A(4) activity, hepatic microsomes olism, 327 (humans), 631 Sequential metabolism, kinetics, 166 1,l,l,2-Tetrafluoroethane, inhaled, disposition, healthy subjects and pa- Sevoflurane, biotransformation, neonate liver slices (rat), 497 tients with chronic airflow limitation, 832 Sex, use of “gender” as synonym for (letter to the editor), 1007 Tetrahydrocannabinol, metabolites, brain kinetics, effect of cannabidiol Short-chain aralkyl sulfides, (S)-sulfoxidation, selectivity of flavin-con- pretreatment (mice), 825 mining monooxygenase 5, 1431 Theophylline, elimination, effects of chronic left ventricular failure (rats), Sigma receptor antagonist, novel, DuP 734, pharmacokinetics and presys- 485 temic first-pass elimination (rats), 603 Thienodiazepine platelet-activating factor receptor antagonist, interspe- SK&F 107461, metabolites, characterization using liquid chromatogra- cies scaling, 776 phy/mass spectrometry (rats), 799 Thiopurine methyltransferase, pharmacogenetics, cloning of human liver Small intestine cDNA and processed pseudogene on human chromosome 18q2l .1, metabolism of tacrolimus, cytochrome P450, drug interactions, and 398 interindividual variability, 1315 Thromboxane A2 receptor antagonist, (+)-S-l45, metabolic pathway, in mucosa, metabolism of [‘4C]l,3-dinitrobenzene in vitro vitro studies, evidence for two independent pathways in peroxiso- (rats), 982 mal a-oxidation, 1195 role in first-pass uptake and systemic clearance of propranolol (rabbits), Tiamulin, induction and inhibition of cytochrome P450 3A, studies in 279 primary hepatocyte cultures and liver microsomes (pigs), 542 Sodium mercaptoundecahydrododecaborate, pharmacokinetics, after in- Tirilazad mesylate, in vitro metabolism, contribution of cytochrome travenous injection (rats), 1368 P4502C1 1 and 4-5o-reductase (rats), 383 1448 SUBJECT INDEX

Tissue distribution studies Valproic acid, pharmacokinetics, pregnant sheep, after maternal and fetal relevance (letter to the editor), 159 intravenous bolus administration, 1383 relevance, utility of radioassay combined with autoradiography, 885 Verapamil, -infused isolated livers, input rate-dependent stereoselective Tocainide, as inhibitor of liver CYP1A1 activity, relative potency (rats), pharmacokinetics, 637 (rats), 637 1335 Verlukast (MK-0679), conjugation with glutathione, liver and kidney Tolbutamide, rates of oxidation, liver slices (rats), 393 cytosols and excretion in bile (rats), 1085 Tolmetin glucuronide, reactivity with human serum albumin, identifica- Vitamin E analog, MDL 74,405, disposition and cardioselectivity after tion of binding sites and mechanisms of reaction, 369 intravenous infusion (rats, dogs), 757 Tolualdehydes, oxidation to toluic acids, catalysis by cytochrome P450- dependent aldehyde oxygenase, liver (mice), 261 R-Warfarin, metabolism, as probe, cytochromes P450 1A1 and P450 1A2 Toluic acids, oxidation of tolualdehydes to, catalysis by cytochrome (humans), 1339 P450-dependent aldehyde oxygenase, liver (mice), 261 (S)-Warfarin, metabolism, inhibition by sulfinpyrazone and metabolites, Topiramate, pharmacokinetics and bioavailability (dogs), 90 659 Trichioroethylene, glutathione-dependent metabolism, isolated liver and WR 1995, metabolism, side-chain hydroxylation, 18 kidney cells, role in mitochondrial and cellular toxicity (rats), 846 WR 238605, metabolism, liver microsomes (rats), 1 Trifluoroacetic acid, trace, utility to enhance quality of proton NMR WR 6026, metabolism, side-chain hydroxylation, 18 spectra of xenobiotic metabolites, 1004 Xenobiotics 2,3,5-(Triglutathion-S-yl)hydroquinone, -mediated nephrotoxicity, spe- biotransformation, minimal effects of aldose reductase inhibitors, sub- cies susceptibility to, metabolism as determinant, role of N- acety- acute topical-ocular dosing (rabbits), 1094 lation and N-deacetylation, 1136 enhanced expression of cytochrome P450 2E1 and 2Bl/2B2, primary Tumor cells, cytosolic class 3 aldehyde dehydrogenases obtained from, cultured hepatocytes (rats), 681 human breast adenocarcinoma MCF-7/0 cells electroporated with, metabolites, proton NMR spectra, quality enhancement, utility of trace sensitivity to mafosfamide, 1080 trifluoroacetic acid, 1004 Xenopus laevis, model system for study of embryonic retinoid metabolism UGT1 .4 protein, expressed human, catalyzes formation of quaternary embryonic metabolism of a11-trans-3,4-didehydroretinol to all- trans- ammonium-linked glucuronides, 299 3,4-didehydroretinoic acid, 83 Urine embryonic metabolism of 9-cis- and all-trans-retinals and retinols to chromium screening (letters to the editor), 607 their corresponding acid forms, 72 excretion of cicletanine, stereochemical aspects (rats), 988 isomerization and metabolism of all-trans-retinoic acid and 9- cis reti- metabolites of N,N-diethylbenzamide, detection by NMR spectroscopy noic acid, and dysmorphogenic effects on embryos during neuru- (rats), 1188 lation, 1058 metabolites of N-ethylbenzamide, detection by NMR spectroscopy (rats), 1188 YM175, pharmacokinetics, (rats, dogs), 1214 metabolites of L-735,524 (humans), 266 metabolites of oral 9-cis-retinoic acid, identification (humans), 887 Zileuton metabolites of phenobarbital, phenobarbital N-glucuronides (mice), 548 isomers, stereoselective glucuronidation, hepatic microsomes (humans), recovery of 3-hydroxypyridin-4-one chelating agents, effect of iron 149 overload (rats), 314 metabolism, liver cytochrome P450 enzymes involved in, identification Uterus, luminal epithelium, induction of catechol-O- methyltransferase by of(humans), 1163 progesterone, inhibition by RU-486 (rats), 430 Zolpidem, oxidative metabolism by human liver cytochrome P450s, 1253 Copyright © 1995 by The American Society for Pharmacology and Experimental Therapeutics t

1

‘-a

r. ‘r I hHE JOURNALOF‘ JPEFisrespectewor1doveras DUADUA(AINV , oneo’’ azthjouriiaI F I1I4RIUI4WLW 1 j- thE co1ogy. Readers

ANDEXPERIMENTAL aspects of ThERAPEUTICS biological systems, inc1udi: autonomic pharmacc. Editor: John Harvey, PhD, analgesia

The Medical College of Pennsylvania behavioral pharmacology .-. - cardiovasculijhnacology

, cellular phartMo1 k ,‘ chemotherapy : Yes! Please start my subscription. I . Avoid future rate increases and ensure I . idmr naco1ogy uninterrupted service -enter your I

‘ drugabse ‘‘- - - I multiyear subscription today! The Journal of Pharmacology and dnig metabolism & di lion I Experimental Therapeutics (monthly) I gastrointestinal p - V Individual 5190/ year immunopharmaco1 E Institutional $370/year I’ - (Add $75/yr. for Stg outside’ the U.S.: ,. ----------

in Canada, also add 7 ‘ GST) r New Subscription Renewal , rena& i..f E 3 years E 2 years E 1 year . -- . toxicology PAYMENT OPTIONS: I, E Check enclosed (payable to Williams & Wilkins) Li Bill me Am Ex MC fl VISA 1PET is valuable nadingfor ‘ academic, industrial and dinical pharmacologists as well as toxicolo- CardS Exp. date gists. Thejoumal deserves a place in every phaimaceulica1a Signature I P.O.# logical reseaithIabor ma

Address I rbycr City I State! Zip!Country I L-FREE 1-800-63 MD,ME,and IL subscribers mustadd state salestax. Subscriptions outside the U S. must be prepaid in U.S dollars only In Japan, contact Igaku-Shoin America. Outsi MYW Ltd (03) 5689-5400. Rates valid through October 31 . 1996 : 1-410-36 /1 Discounts available to members on all ASPET publications. SAVE 10% when ordering two SAVE 15% when ordering three SAVE 20’/ when ‘1 intemat ordering all four o :“ Return coupon to: Williams & Wilkins, A Waverly Company, T P.O. Boo 23291, Baltimore, MD 21203-9990. Loni 5-2357, . PT 555)5 Printed in LSA SeJ044Z